Bipolar disorder (BD) is one of the most common and persistent psychiatric disorders. Earlyonset BD has been shown to be the most severe and familial form. We recently carried out a whole-genome linkage analysis on sibpairs affected by early-onset BD and showed that the 20p12 region was more frequently shared in our families than expected by chance. The synaptosomal-associated protein SNAP25 is a presynaptic plasma membrane protein essential for the triggering of vesicular fusion and neurotransmitter release, and for which abnormal protein levels have been reported in postmortem studies of bipolar patients. We hypothesised that variations in the gene encoding SNAP25, located on chromosome 20p12, might influence the susceptibility to early-onset BD. We screened SNAP25 for mutations and performed a case-control association study in 197 patients with early-onset BD, 202 patients with late-onset BD and 136 unaffected subjects. In addition, we analysed the expression level of the two SNAP25 isoforms in 60 brains. We showed that one variant, located in the promoter region, was associated with early-onset BD but not with the late-onset subgroup. In addition, individuals homozygous for this variant showed a significant higher SNAP25b expression level in prefrontal cortex. These results show that variations in SNAP25, associated with an increased gene expression level in prefrontal cortex, might predispose to early-onset BD. Further analyses of this gene, as well as analysis of genes encoding for the SNAP25 protein partners, are required to understand the impact of such molecular mechanisms in BD.
Introduction
Bipolar disorder (BD) affects 1-5% of the general population and is one of the most severe and frequent psychiatric disorders. It is characterised by alternating episodes of major depression and elevated mood (hypomanic or manic episodes). 1 Twin, family and adoption studies have suggested that genetic factors are involved in BD, but no causal mutation has yet been identified. 2 The identification of susceptibility genes has been hampered by a lack of consensus concerning the most valid phenotype to investigate and by the unknown genetic validity of the classical clinical classifications. To disentangle the genetic and clinical heterogeneity of the disorder, a clinical approach based on candidate symptoms has been proposed. 3 Age at onset (AAO; that is age at the first mood episode) is one of the most relevant indicators to identify homogeneous subgroups that may reduce the underlying genetic heterogeneity. Three AAO subgroups have been identified for BD [4] [5] [6] and there is strong evidence showing that genetic factors make a greater contribution to the disease in the early-onset subgroup than in the other subgroups. 7 We recently carried out a whole-genome linkage analysis in early-onset BD sibpairs, and identified six regions with a suggestive multipoint nonparametric logarithm of the odds ratio-score. 8 These regions included the 20p12 region, already reported by three independent studies to contain a gene conferring susceptibility to BD. [9] [10] [11] The gene encoding the synaptosomal-associated protein of 25 kDa (SNAP25) is located in this region.
Several arguments suggest that SNAP25 is a strong candidate gene for BD. First, SNAP25 is a presynaptic plasma membrane protein essential for the triggering of vesicular fusion and neurotransmitter release. 12, 13 Second, postmortem studies have shown modifica-tions of SNAP25 protein levels in some brain regions of bipolar patients. 14, 15 Third, SNAP25 gene has been widely associated with attention-deficit hyperactivity disorder (ADHD), which is known to share genetic susceptibility with early-onset BD. [16] [17] [18] We analysed SNAP25 as a candidate gene for susceptibility to BD and, more specifically, to earlyonset BD. We screened this gene for mutations and performed a case-control association study taking into account the AAO of the disease. Finally, we analysed the influence of associated susceptibility alleles on the expression level of SNAP25 in human prefrontal cortices.
Materials and methods

Subjects
Patients meeting Diagnostic and Statistical Manual for Mental Disorders, 4th edition (DSM-IV) criteria 1 for type I or II BD consecutively admitted to three French university-affiliated psychiatry departments (Paris-Créteil, Bordeaux and Nancy) were interviewed by trained psychiatrists, using the French version of the Diagnostic Interview for Genetic Studies (DIGS version 3.0). 19 All patients were normothymic at inclusion (that is having a Montgomery-Asberg Depression Rating Scale 20 score and a Mania Rating Scale 21 score of no more than five). The healthy controls were recruited from blood donors at the Pitié-Salpêtrière and Henri Mondor Hospitals (France). Controls were interviewed with the DIGS, and asked about family history of psychiatric disorders, using the National Institute for Mental Health Family Interview for Genetic Studies. 22 Only controls, with no personal history of psychiatric disorders and no family history (first-degree) of affective disorders or suicidal behaviour, were included. All patients and controls were of French descent, with at least three grandparents from mainland France. The Research Ethics Board of Pitié-Salpêtrière Hospital reviewed and approved this study. Written informed consent was obtained from all participating subjects.
Definition of age at onset of bipolar disorder For association studies, AAO of BD was defined as the age at which the first mood episode (depressive, manic or hypomanic) occurred, as determined by reviewing medical case notes and information obtained with the DIGS. The threshold for early-onset BD (AAO before the age of 22 years) was chosen on the basis of previous admixture analyses, this threshold being defined in four independent samples. [4] [5] [6] 23 These studies identified three 25 Diagnoses were made according to the DSM-IV. 1 A summary of the demographic and clinical information of subjects used in this study is described in Supplementary Table S1 . The samples were coded and genotypes and disease status were known only after expression analyses.
Mutation screening and genotyping Genomic DNA was isolated from blood lymphocytes or B-lymphoblastoid cell lines from independent cases and controls, using the Nucleon BACC3 kit (GE HealthCare, Chalfont St Giles, UK). We first sequenced the whole SNAP25 genomic region (eight coding exons including one alternative splicing exon, one 5 0 -untranslated exon, flanking intronic regions and 1400 bp upstream from the transcription start site) in 31 individuals with early-onset BD, to identify informative single nucleotide polymorphisms (SNPs) in the SNAP25 gene and to avoid ascertainment bias in the choice of markers to be tested. All the primers used for PCR amplification and sequence analysis are available on request. The sequence of the SNAP25 gene was analysed by direct sequencing of the PCR products, using the BigDye terminator v3.1 cycle sequencing kit and a 16-Capillary ABI PRISM 3100 Genetic Analyser (Applied Biosystems, Foster City, CA, USA). We used polymorphisms with a minor allele frequency (MAF) greater than 0.05 to convert unphased genotypic data into haplotypes, using the accelerated expectation maximisation algorithm implemented in Haploview v3.32. 26 We evaluated the accuracy of the this algorithm, by carrying out haplotype reconstruction in parallel, using the Bayesian statistical method implemented in Phase v.2.1.1. 27 Equivalent results were obtained with both methods, with high levels of statistical support for all haplotypes. We defined the minimum number of SNPs accounting for the largest proportion of haplotypic diversity, using Haploview v3.32. Seven haplotype-tagging SNPs (htSNPs) were then selected for the genotyping of the entire panel of 545 individuals. DNA samples were genotyped by TaqMan SNP genotyping assays on a 7000 real-time PCR system (Applied Biosystems). Probes were either obtained from commercial sources (SNP4, SNP6, SNP8, SNP12 and SNP15) or were custom-made (SNP1 and SNP14; Applied Biosystems).
Quantitative real-time PCR Expression levels of the two isoforms of SNAP25 were determined using TaqMan gene expression assays (Applied Biosystems), with probes specifically hybridising SNAP25a (Hs00938959_m1) and SNAP25b (Hs00938964_m1). Normalisation was performed using an endogenous housekeeping gene encoding Common threshold fluorescence for all the samples was set into the exponential phase of the amplification and determined the C T , corresponding to the number of amplification cycles needed to reach this threshold. All reactions were performed in triplicate and the mean value of C T was used for subsequent analysis. Relative gene expression quantification was performed using the 2 ÀDDC T method. 28 For the calibrator, first strand cDNA was generated from 1 mg of human brain total RNA (Clontech Laboratories Inc., Mountain View, CA, USA) using random hexamers and 200 U of SuperScript III reverse transcriptase (Invitrogen, Carlsbad, CA, USA) in a final reaction volume of 20 ml. The cDNA was treated with 10 U of ribonuclease H (Invitrogen) to remove bound RNA template and diluted to 1/25. 
Statistical analyses
Results
Mutation screening
Direct sequencing of samples from 31 patients with early-onset BD led to the detection of one synonymous and fourteen noncoding variants (Supplementary Table S2 ; Figure 1 ). Four of these variants (SNP1-4) were located in the promoter region, one in exon 6 (SNP9), seven in introns flanking coding exons and three in the 3 0 untranslated region (SNP13-15). Of these 15, 10 SNPs had a MAF higher than 0.05. We identified htSNPs by calculating the linkage disequilibrium between SNPs. Two linkage disequilibrium blocks had r 2 values > 0.8 (SNP6, SNP9 and SNP10, and SNP13 and SNP15), resulting in the definition of seven htSNPs (see Supplementary Table S2 ; Figure 1 ). Three amino-acid changes were reported in public databases, in exons 2, 5a and 6. We therefore screened these exons for mutations in an additional sample of 78 individuals (43 early-onset BD and 35 late-onset BD). No amino-acid change was observed in these individuals.
Association study
The seven htSNPs (SNP1, SNP4, SNP6, SNP8, SNP12, SNP14 and SNP15) were tested for association with BD subgroups. All SNPs were in Hardy-Weinberg equilibrium in control populations. One of the seven SNPs (SNP14) was not in Hardy-Weinberg equilibrium in affected subjects (P = 0.017). Patients with early-onset (N = 197) and late-onset (N = 202) BD were compared with unaffected individuals (N = 136) in case-control studies (Supplementary Table S3 ). Allele distribution for SNP4 and for SNP12 differed significantly between the early-onset and control groups (P = 0.005 and P = 0.04, respectively; Table 1 ), whereas no association was observed in the late-onset subgroup (P = 0.22 and P = 0.63, respectively; Supplementary Table S4 ). For SNP4, the result remained significant in early-onset subgroup after correction for multiple testing (corrected empirical P-value for 100 000 permutations P c = 0.03). Significant genotypic association was observed only for SNP4 (P = 0.017), for which the 'CC' genotype was more frequent in early-onset cases (51%) than in controls (39%).
Although not significant, a weak difference was observed for allele frequencies of SNP4 between subjects affected with early-onset and those affected with late-onset BD (P = 0.08). We also carried out an overall one-way ANOVA for the whole sample of BD patients, and found significant differences in mean AAO as a function of SNP4 genotype (F = 3.371; d.f. = 2; P = 0.035; Figure 2) .
We carried out a haplotype analysis for the earlyonset subgroup, using two-to seven-marker haplotype windows, which we slid along the SNAP25 gene in a 5 0 -3 0 direction. Several haplotypes gave significant P-values (not shown). The most significant association was obtained for a four-marker haplotype window (SNP1-SNP4-SNP6-SNP8 'GAAA' haplotype, P = 0.002, Table 2 ).
Population stratification
Our control population was ethnically matched to the cases, and we expected only moderate stratification for our population. Nonetheless, we assessed the risk of false positive results because of population stratification, by genotyping 15 unlinked genetic markers randomly distributed in the genome and with allele frequencies similar to those of SNP4 or SNP12 (Supplementary Table S5 ). The mean w 2 -value (m) across these 15 loci, representing the level of stratification, 29 was 1.17 (P = 0.28), suggesting that the two groups were not genetically different. After direct quantitative correction for stratification, the differences between our cases and controls remained significant for SNP4 (P = 0.009), and were marginal for SNP12 (P = 0.06). Thus, population stratification is unlikely to account for the observed association between SNAP25 polymorphisms and early-onset BD.
Expression analysis
The SNAP25 promoter region has been previously defined to span 2073 bp upstream to the transcription start site, 30 including the SNP4. To determine whether this SNP may affect the mRNA expression in patients' brains, we analysed the transcript level of the two isoforms of SNAP25, SNPA25a and SNAP25b, in the prefrontal cortex of patients affected with BD (N = 30) and unaffected control individuals (n = 30). The allelic and genotypic frequencies of SNP4 were similar in the brain sample and in our populations, for both affected and unaffected subjects (P exact = 0.32 and P exact = 0.83, respectively, for genotypic distributions), showing a higher frequency of the 'CC' genotype in patients than in controls (Supplementary Table S6 ). The expression level of SNAP25b was higher in individuals homozygous for the 'C' allele of SNP4, as compared to those carrying either 'AA' or 'CA' genotypes (one-way ANOVA, F = 4.61; d.f. = 1; P = 0.04), whereas no significant difference was observed for SNAP25a (one-way ANOVA, F = 2.17; d.f. = 1; P = 0.15), nor for the SNAP25b:SNAP25a ratio (one-way ANOVA, F = 1.50; d.f. = 1; P = 0.23). We performed a similar analysis taking into account the disease status (affected or unaffected) in a multivariate model, and showed that the influence of genotypes on the mRNA expression level of SNAP25b in prefrontal cortex remained significant (two-way ANOVA, F = 4.19; d.f. = 1; P = 0.045; Figure 3 ). In this analysis, neither an effect of the disease status (P = 0.21) nor an interaction between the genotype and the disease status (P = 0.87) was observed. As our genetic results showed a significant increase of the SNP4 'CC' genotype only in patients with early-onset BD, we carried out a secondary analysis to compare the three diagnostic groups (controls, late-onset BD and early-onset BD). We did not find any significant influence of these subgroups on the expression level of SNAP25a and SNPA25b (one-way ANOVA, F SNAP25a = 0.99; d.f. SNAP25a = 2; P SNAP25a = 0.38, and F SNAP25b = 0.95; d.f. SNAP25b = 2; P SNAP25b = 0.39), although the small sample size hampered the interpretation of these results. A previous study reported a significant increase of SNAP25 and syntaxin interaction in subjects who died by suicide. 31 Thus, we carried out an additional analysis taking into account the suicide status of subjects. However, no significant effect of suicide status was observed on this sample (Student's t-test, P SNAP25a = 0.58 and P SNAP25b = 0.36). Finally, no significant correlation was detected between SNAP25a and SNAP25b expression levels and age, PMI, RI and brain pH (data not shown). Altogether, these results showed that the SNAP25b expression level was only dependant on the subjects' SNP4 genotype.
Discussion
We provide here evidence for an association between early-onset BD and a SNP located in the promoter region of the SNAP25 gene. This association was not observed when considering late-onset BD, suggesting that this susceptibility variant might be involved only in the early-onset subgroup of patients. These results are consistent with those of our previous genomewide scan for early-onset BD, 8 and strengthened by three other genome-wide scans reporting linkage on chromosome 20p12.
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The SNP, for which the highest significant association was observed (SNP4), is located in a CpG island, spanning the promoter region of the gene, and may affect the transcription level of SNAP25. Using quantitative RT-PCR analysis on brain samples, we showed that individuals with 'CC' genotype showed a significant increase in mRNA level of the major isoform of SNAP25 in adult (SNAP25b) in prefrontal cortex. These results are consistent with the significant increase in SNAP25 protein level previously reported in Brodmann's area 9 (dorsolateral prefrontal cortex) in patients with BD, 15 as cellular and animal studies showed that variations in mRNA levels of SNAP25 correspond to equivalent variation in protein levels. 32, 33 The SNP4 is located between two AP-1 consensusbinding sequences in a region that contributes to the repression of the SNAP25 transcription by binding of POU4F2 (also called Brn-3b). 30, 34 This protein is a member of the Pict-Oct-Unc (POU) transcription factor family that involved in the development of the mammalian nervous system and for which an overexpression results in a failure of SNAP25 activation and neurite outgrowth. 35 Thus, SNP4 might result in a modification in the binding affinity of a transcriptional factor, such as POU4F2, leading to the increase of SNAP25b expression level that we observed in prefrontal cortex of homozygous subjects for the 'C' allele of SNP4.
In mice, SNAP25 is regulated during brain growth and synaptogenesis at the level of expression and by Bold numbers correspond to significant P-values (ap0.05). alternative splicing between tandem exon 5. 36 This results in a developmental switch between 1 and 3 weeks of age from expression of predominantly SNAP25a to SNAP25b transcripts that ultimately constitute more than 80% of SNAP25 mRNA in mouse adult brain. These two isoforms diverge only for nine amino acids in a domain involved in membrane association and disassembly, after exocytosis, of the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex. [37] [38] [39] In individuals homozygous for the 'C' allele, we observed that only SNAP25b is significantly increased. Interestingly, in absence of this isoform, 75% of mice die before 5 weeks of age and surviving animals present alteration in synaptic maturation as well as deficit in synaptic transmission. 40 In addition, overexpression of SNAP25 in cultured hippocampal neurons resulted also in impaired synaptic transmission. 41 Altogether, these results suggest that an increased SNAP25b level might impair synaptic maturation or neurotransmission, which in turns might influence either the risk of developing BD or the AAO in vulnerable individuals. This increase might also reflect an abnormal switch of SNAP25a to SNAP25b during adolescence, consistent with the well-documented increase of the susceptibility to BD during and after puberty.
There is compelling evidence demonstrating abnormal serotonergic, dopaminergic and noradrenergic neurotransmission in BD. 42 Theses abnormal patterns of neurotransmission may be underpinned by abnormal exocytosis phenomena and thus linked to SNAP25 dysfunction, as this protein is involved in vesicle docking and exocytosis. Interestingly, coloboma mice have a 2 cM deletion on chromosome 2, including the SNAP25 gene. 32 Raber et al. 12 studied the release of several neurotransmitters in heterozygous mice (Cm/ þ ), expressing 50% of the SNAP25 protein level, and showed that depolarisation failed to induce dopamine release and induced significantly lower than normal amounts of serotonin from the dorsal striatum. These results were recently confirmed by Fortin et al., 43 who showed that SNAP25 was required for dopamine release from rat neurons in culture. Therefore, polymorphisms in the SNAP25 gene may influence the susceptibility to BD through the modification of one or several monoaminergic neurotransmission systems in specific brain areas. Further experiments are required to determine, which neurotransmission systems are specifically altered in early-onset BD patients, carrying the SNAP25 susceptibility allele.
Polymorphisms in the SNAP25 gene have been shown to be associated with ADHD. 16, [44] [45] [46] A high comorbidity has been reported between ADHD and BD, more specifically with early-onset BD. 47 Therefore, our results suggest that SNAP25 might be a common susceptibility factors for these psychiatric disorders. These data are strengthened by the recent results obtained by Kim et al., 48 showing that comorbidity with major depressive disorder may enhance detection of the association between SNAP25 and ADHD. Further association studies on clinically well-defined populations will be necessary to determine how these different phenotypes are influenced by the same gene.
In conclusion, we report here an association between early-onset BD and the -523C/A variant of the SNAP25 gene promoter, as well as an association between this polymorphism and the expression level of SNAP25b isoform in human prefrontal cortex. This raises the hypothesis that the SNAP25b expression level in prefrontal cortex, which strongly influences neurotransmitter release, might modify the risk to develop an early-onset BD. These results require confirmation in larger samples to identify more functional variants accounting for the pathophysiology of BD. Furthermore, functional explorations of SNAP25 in bipolar patients and animal models will be necessary to explore, in more details, the role of variations in this gene in BD and other psychiatric disorders.
